The role and efficacy of Penpulimab

Penpulimab (Penpulimab) is a new PD-1 immune checkpoint inhibitor that has shown encouraging efficacy in the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL) and recurrent or metastatic nasopharyngeal carcinoma (NPC). Its mechanism of action mainly relies on blocking PD-1 receptors on the surface of T cells. PD-1 is an important immune checkpoint protein. Under normal circumstances, it negatively regulates T cell activity by binding to its ligand PD-L1 or PD-L2, thus preventing the immune system from attacking normal tissues. However, many cancer cells take advantage of this mechanism to evade the immune system's attack by expressing PD-L1 or PD-L2 in large quantities, causing T cells to become inactive and the tumor to survive and expand.

Penpilimab specifically binds PD-1 receptor, effectively blocking its binding to PD-L1 and PD-L2. This blocking effect can relieve the inhibitory signals received by T cells and reactivate the anti-tumor activity of T cells, allowing them to recognize and destroy cancer cells. Unlike traditional chemotherapy drugs, penpilimab does not directly kill cancer cells, but exerts its anti-cancer effect by regulating and enhancing the body's own immune response. This approach not only makes the treatment effect more sustainable, but may also bring about deeper relief.

In clinical application, penpilimab has demonstrated a high objective response rate and durable disease control effect, providing a new and effective treatment option, especially for patients who have failed traditional treatments. What is more worth mentioning is that compared with some early PD-1 inhibitors, penpillimab has been optimized in antibody structure and theoretically reduces antibody-dependent cellular toxicity (ADCC) and complement-dependent cytotoxicity (CDC), which helps reduce the risk of certain immune-related side effects, thus improving the safety of treatment and patient tolerance.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC11189389/